Demantin

Quick links to important sections

Demantin

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demantin

What is Demantin?

Demantin is a medication primarily used in the management of moderate to severe dementia associated with Alzheimer's disease. It belongs to a class of drugs known as NMDA (N-methyl-D-aspartate) receptor antagonists. Unlike some other treatments for cognitive decline, Demantin works by regulating the activity of glutamate, a chemical messenger in the brain involved in learning and memory.

Mechanism of Action

In a healthy brain, glutamate attaches to NMDA receptors to allow the flow of signals necessary for information processing. However, in patients with Alzheimer's disease, excessive amounts of glutamate can lead to overstimulation of these receptors. This continuous activation can prevent the transmission of clear signals and may contribute to nerve cell damage over time.

Demantin acts by partially blocking these NMDA receptors. By shielding the receptors from overstimulation, the medication helps to restore a more normal pattern of signaling. This process is intended to help the brain process information more clearly and may assist in maintaining daily functional abilities for a period of time.

Therapeutic Intent

The primary goal of Demantin therapy is to manage the symptoms of cognitive decline. While it is not a cure for Alzheimer's disease and does not stop the underlying progression of the condition, it is used to help improve or stabilize:

  • Memory and concentration
  • Language and reasoning abilities
  • The performance of daily tasks

By modulating brain chemistry, the medication aims to provide a better quality of life for patients and their caregivers by addressing the symptomatic aspects of neurodegeneration.

Regulatory References

  1. NIH Review
  2. NIH MedlinePlus Drug Information
  3. EMA Ebixa (Memantine) EPAR

What side effects are possible with Demantin?

Possible side effects and safety information

The safety profile of Demantin (Memantine Hydrochloride) is officially classified by regulatory authorities based on the frequency of documented adverse reactions, which are grouped according to the physiological system affected.

Official Frequency Classification of Adverse Reactions

Adverse effects are categorized by incidence, affecting multiple System-Organ Classes including the nervous, psychiatric, and vascular systems.

Classification Examples of Documented Adverse Reactions
Common Dizziness, Headache, Somnolence (Drowsiness), Constipation, Hypertension, Dyspnoea (Difficulty breathing).
Uncommon Confusion, Hallucinations, Vomiting, Fatigue, Gait disturbance, Venous thromboembolism (VTE), Cardiac failure, Fungal infections.
Rare/Very Rare Seizures, Agranulocytosis.
Not Known Pancreatitis, Psychotic reactions, Hepatitis.

Serious adverse reactions, though rare or uncommon, are highlighted in regulatory labeling, including Seizures, Cardiac failure, VTE, and severe conditions like Hepatitis and Pancreatitis.

Population-Specific Safety Considerations

The official labeling outlines specific safety constraints related to underlying patient health. The medicine is contraindicated (should not be used) in individuals with severe hepatic impairment (severe liver disease). Caution is required for use in mild to moderate hepatic impairment, and dose adjustments are necessary for patients experiencing moderate to severe renal impairment (kidney function issues).

Time-Related Safety Patterns

Regulatory documents note that some effects may be linked to the timing of exposure. For instance, reactions like Headache are often observed at the beginning of therapy, and episodes of Confusion or Hallucinations may occur early in treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Demantin (Memantine Hydrochloride) outlines specific manifestations and mandatory actions required in cases of overdose. The profile is defined by the CNS effects and the need for supportive care, as no specific antidote is available for intoxication.


Documented Manifestations and Outcomes Regulatory Action Required
Documented CNS Overstimulation is the primary risk. Clinical signs include confusion, somnolence, agitation, hallucination, vertigo, gait disturbance, vomiting, and diarrhoea. Severe outcomes include psychosis, proconvulsiveness, unconsciousness, and, in extreme cases, coma [EMA SmPC]. Seek immediate medical attention or call a poison control center right away. A large overdose requires going to the nearest hospital emergency room [NIH/MedlinePlus].

Management is strictly symptomatic and supportive treatment. Officially described clinical procedures to remove unabsorbed material include gastric lavage and the administration of activated charcoal ( carbo medicinalis). A specific concern is the risk of drug accumulation in patients with conditions that raise urine pH, which can significantly reduce drug clearance. This requires continuous medical observation when severe manifestations of overdose are present, particularly for signs of CNS overstimulation [FDA Prescribing Information].

Therapeutic Uses of Demantin

What Demantin Treats: Main Uses and Benefits

Demantin is commonly used in the therapeutic management of neurodegenerative disorders, with a focus on patients experiencing moderate to severe stages of Alzheimer's disease. The primary clinical indications for which Demantin is applied in addressing are Alzheimer’s disease, vascular dementia, and mixed forms of dementia, typically when the condition has progressed to a pronounced stage.

The medication is considered relevant for patients experiencing symptoms that affect memory, intellectual ability, and behavior. The primary therapeutic benefit contributes to easing the overall symptom load by offering supportive relief to stabilize the symptomatic course of the illness.

The medication is applied in addressing key symptom clusters that include pronounced memory loss, impaired thinking and reasoning, and chronic confusion. By supporting the management of these severe cognitive deficits, Demantin assists with maintaining functional stability and helps patients cope more steadily.

“The goal is to maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Cognitive Decline Focus of Symptom Management
Primary Indication Moderate to severe Alzheimer's disease
Symptom Cluster Impaired memory, confusion, reasoning
Patient Benefit Assists with maintaining functional stability
Typical Context Long-term chronic maintenance therapy

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Demantin (Memantine Hydrochloride) eligibility is strictly defined by regulatory authorities, outlining who can safely use the medicine, who must not, and which populations require restricted use. Use is generally established for adults 18 years and older.

Contraindications and Absolute Prohibitions

The medicine is contraindicated for patients with a known hypersensitivity or allergy to memantine hydrochloride or any of the inactive ingredients in the formulation.

Age and Physiological Restrictions

Population Group Regulatory Status
Children & Adolescents (Under 18) Not recommended; safety and effectiveness not established.
Pregnant Women Should not be used unless clearly necessary, due to insufficient data.
Breast-feeding Women Should not breast-feed, as the substance likely passes into milk.

Conditions Requiring Restricted Use

Patients with severe renal impairment must use the medicine under a reduced maximum dose as specified in the labeling. Use is not recommended in patients with severe hepatic impairment due to limited data and potential accumulation. Caution and close supervision are also required for patients with a history of seizures, specific cardiovascular conditions (uncontrolled hypertension, uncompensated heart failure), or conditions that significantly alter urine pH.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Demantin (Memantine Hydrochloride) interaction profile is defined by officially documented effects on the central nervous system (CNS) and alterations in its renal elimination. Regulatory documentation advises against co-administration with other NMDA-antagonists such as Amantadine, Ketamine, and Dextromethorphan due to the potential for pronounced CNS-related adverse reactions, including pharmacotoxic psychosis.


Pharmacodynamic and Elimination Interactions

Interaction Type Interacting Substances/Conditions Official Regulatory Description
Enhanced CNS Effects L-Dopa, Dopaminergic Agonists Effects may be enhanced by co-administration.
Altered Drug Clearance Alkalinizing Agents (e.g., Sodium Bicarbonate, Carbonic Anhydrase Inhibitors) May decrease urinary elimination, resulting in increased Demantin plasma levels.
Transporter Competition Cimetidine, Quinidine, Ranitidine, Procainamide Potential interaction due to competition for the shared renal cationic transport system.
Monitoring Required Warfarin (Oral Anticoagulants) Close monitoring of International Normalized Ratio (INR) is advised due to reported increases.

Officially documented interactions also note that the effects of Barbiturates and certain Neuroleptics may be reduced. For patients with Severe Renal Impairment (CrCl 5–29 mL/min), the risk of drug accumulation is heightened due to impaired clearance. There is no documented interaction with food that affects absorption; however, drastic changes in diet that significantly alter urine pH may necessitate clinical oversight.

Mechanism of Action

Memantine (Demantin) regulates the activity of the glutamatergic system within the central nervous system through ion channel blockade.


Activity-Dependent Blockade of the NMDA Receptor

The drug acts as a unique uncompetitive antagonist that blocks the NMDA receptor, which is an ion channel activated by the excitatory neurotransmitter, glutamate. The mechanism is voltage-dependent, meaning Memantine preferentially plugs the receptor channel pore when it is persistently open due to chronic electrical activity. This selective engagement of the receptor results in a reduction of chronic, pathological electrical activity within neural circuits.


️ Preventing Cellular Ca^2+ Overload

By physically blocking the NMDA receptor channel, Memantine prevents the excessive and sustained influx of Ca^2+ ions into the nerve cell. This action interrupts the pathological cascade known as excitotoxicity—neuron damage caused by chronic over-stimulation. This mitigation of Ca^2+-mediated stress factors supports the cellular integrity of the neurons.


Preferential Blockade of Pathological Signaling

Memantine's kinetic profile, characterized by its low affinity and fast off-rate, is integral to its mechanism. This kinetic profile results in a preferential blockade of sustained pathological stimulation over transient physiological signaling. This ensures the drug rapidly dissociates during brief, low-frequency signaling, while maintaining its block when chronic overactivity is present.

Dosage and Administration Information

How Demantin is Used in Practice: Official Dosing and Administration

Demantin (memantine) is prescribed exclusively for oral administration in adults. The medication is available as immediate-release (IR) tablets, an oral solution, and extended-release (ER) capsules, which require different intake schedules and handling.

Dosing Regimens and Titration

Official guidelines dictate that treatment must begin at a low starting dose and be gradually escalated via a slow titration process to reach the full maintenance level. This is done to establish proper tolerance before reaching the maximum dosage.

Formulation Starting Dose Titration Increment Maintenance Dose Frequency
Immediate-Release (IR) 5 mg once daily Increase by 5 mg 20 mg daily Divided, typically 10 mg twice daily
Extended-Release (ER) 7 mg once daily Increase by 7 mg 28 mg daily Once daily

Dose increases must occur at a minimum interval of one week. The maximum daily dose is 20 mg for IR formulations and 28 mg for ER formulations.

Administration Guidance

Demantin may be taken with or without food. The extended-release capsule must be swallowed whole or its entire contents can be sprinkled onto a spoonful of applesauce and consumed immediately; it must not be chewed, crushed, or divided. The oral solution must be measured using the dedicated dosing device and should not be mixed with any other liquid.

If a single dose is missed, patients should not double the next dose; instead, they should resume the regular schedule. If the medication is stopped for several days, official guidance advises re-initiating the treatment at a lower dose and following the original titration schedule again.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Demantin


Evidence for Use in Moderate to Severe Alzheimer's Disease

The primary body of knowledge for Demantin is derived from short-term, randomized, double-blind, placebo-controlled clinical trials (RCTs). These studies were used in research exploring how symptoms change over time. These studies primarily included older adults with probable Alzheimer's disease who were experiencing moderate to severe cognitive impairment. Researchers examined outcomes related to cognitive function, overall global clinical status, functional ability (such as daily living skills), and behavioral symptom patterns.

Multiple systematic reviews and meta-analyses have consolidated the findings from these core RCTs. This evidence contributes to understanding symptom patterns by reporting how symptoms were tracked in the observed populations when comparing the Demantin group to the placebo group. The findings describe patterns observed in the studies related to measurements of difference across the measured domains. Research highlights changes measured during the study period across these key domains. However, the size of the difference reported in these studies has been described in scientific literature as modest or small relative to the assessment scales. The research's ability to monitor the course of the condition over many years is limited, as the evidence is derived primarily from studies with a short-term follow-up duration, typically around 24 to 28 weeks.


️ Research Findings in Vascular Dementia

Demantin was also studied for its use in managing symptoms in patients with vascular dementia (VaD). The evidence base for this indication is not as comprehensive and includes a core set of short-term, randomized, placebo-controlled trials, primarily in patients categorized in the mild to moderate range of cognitive impairment. The research examined outcomes related to functional imbalance by assessing changes in both cognitive function and global clinical status.

Scientific review of this limited data has described a heterogeneity of findings and indicates that evidence quality varies across studies, with a need for greater data volume. As a result, certainty remains low compared to the volume of data available for the primary Alzheimer's disease indication, and comparative evidence is lacking.

Key Studies & References

  1. The NMDA Receptor Antagonist Memantine: A Review of Efficacy and Safety
  2. A randomized, double-blind, placebo-controlled trial of memantine in vascular dementia

Frequently Asked Questions (FAQ)

Common questions about Demantin (FAQ)


Q: Can Demantin be taken with common over-the-counter pain relievers?

Official documentation advises patients to keep a healthcare provider informed about all medicines they are using, including over-the-counter (OTC) pain relievers and supplements. This practice allows a healthcare provider to monitor for potential interactions that may occur when Demantin is taken alongside other substances.


Q: Are there any specific foods or drinks I should avoid while on Demantin?

Demantin can generally be taken with or without food. However, regulatory warnings note that drastic changes in diet or conditions that make the urine highly alkaline can potentially reduce the elimination of the drug from the body. A healthcare provider can offer monitoring if significant dietary changes are made.


Q: What are the long-term effects of taking Demantin?

Clinical trials that supported the initial research into Demantin were primarily short-term studies, typically lasting around 24 to 28 weeks. Research evidence derived from these studies for monitoring effects over many years is limited. Observed patterns are derived from these short-term study periods.


Q: Does Demantin interact with alcohol?

While alcohol is not listed as a primary drug interaction, general guidance advises that patients discuss the consumption of alcohol with their healthcare professional. This allows for an individual assessment of the risk.


Q: Does Demantin interact with common vitamins like Vitamin D or B12?

The official label advises informing a healthcare professional about all vitamins/minerals and herbal products being used. This information allows a healthcare provider to monitor any potential interactions that may arise when Demantin is combined with supplements.


Q: Is Demantin the same type of drug as other medicines for this condition?

No. Demantin is classified as an NMDA Receptor Antagonist, which identifies its unique action in regulating a specific type of neurotransmitter system in the brain. This mechanism of action is distinct from other classes of drugs, such as cholinesterase inhibitors, which may be used for related conditions.


Q: How quickly should I expect Demantin to start having an effect?

The official documents do not state an exact time for the onset of effect. Official dosing dictates that treatment must begin at a low dose and be gradually increased over several weeks. This slow titration process is required to reach the full maintenance dose.


Q: What happens if I stop taking Demantin suddenly?

If the medication is stopped for a period of several days, official guidance advises that treatment should be re-initiated at a lower dose and the original dose escalation schedule should be followed again. Furthermore, official post-marketing reports indicate that behavioral disturbances may occur following abrupt cessation.


Q: Why do some people say Demantin gave them a headache?

Official safety data confirms that Headache is listed as one of the most commonly observed adverse reactions reported in clinical trials. The official safety profile groups side effects by frequency.


Q: Are there different doses of Demantin, and how is that decided?

Yes, official documents define different maintenance doses based on whether the drug is the immediate-release tablet or the extended-release capsule formulation. Additionally, official guidelines specify that the dose may be reduced for patients who have severe renal impairment (kidney issues).


Q: Can Demantin affect my sleep schedule?

Yes, official safety data indicates that Demantin can affect sleep patterns. Regulatory documents list both Somnolence (Drowsiness) and Insomnia (difficulty sleeping) as documented side effects reported during clinical trials.


Q: How is Demantin eliminated from the body?

The drug is primarily eliminated from the body through the urine. Regulatory documents confirm that the majority of an administered dose is excreted in this manner, often in its unchanged form.


Q: What is the difference between Demantin and a supplement?

Demantin is a Prescription-Only Medicine (POM) that has been rigorously evaluated, approved, and regulated by governmental health authorities for specific medical uses. This classification and process are distinct from how dietary supplements are regulated.


Q: Does Demantin have any known effects on mood?

Official documents list potential psychiatric effects such as Confusion and Hallucinations as documented side effects. Furthermore, official safety data notes that unusual changes in mood or behavior may occur.


Q: Does Demantin require regular blood tests?

While not generally required for all users, official documentation advises close monitoring for patients taking certain other medications. Specifically, patients taking the blood thinner Warfarin alongside Demantin require close monitoring of their INR (a blood test).


Q: Are there any common interactions between Demantin and herbal remedies?

The official label advises that patients inform a healthcare professional about all herbal products and supplements being used. This allows a healthcare provider to monitor for potential interactions that could arise when herbal remedies are taken with Demantin.


Q: Are there any known visual side effects from Demantin?

Post-marketing safety surveillance has identified blurred vision as a potential adverse reaction reported with the use of the drug. If this occurs, it is recommended to discuss it with a healthcare professional.


Q: Can Demantin affect blood pressure?

Hypertension (high blood pressure) is listed in the official documentation as a common documented adverse reaction observed in clinical trials. This indicates a potential effect on the vascular system.


Q: Why is Demantin taken only once a day?

The specific Extended-Release (ER) capsule formulation of Demantin is designed to gradually release the active ingredient into the body over a longer period. This formulation is what supports the required once daily intake schedule.

How should Demantin be stored and disposed of?

How to Store and Dispose of Demantin?

The official labeling for Demantin (memantine hydrochloride) specifies strict storage and disposal requirements to ensure product integrity and safety.

Required Storage and Handling

Demantin must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F), protected from excess heat and moisture. The medication must be kept in its original container and the container must remain tightly closed. It is mandatory to store the medication out of the sight and reach of children, and it must not be frozen.

For the oral solution formulation, any unused portion must be discarded 70 days after the bottle is first opened, regardless of the expiration date.

Disposal Instructions

Unused or expired Demantin should not be disposed of in wastewater or general household trash. Disposal must adhere to local regulations for pharmaceutical waste, often through authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Demantin found in:

A-Z Index: